North American Coral Snake Antivenin (equine) Injection, Powder, For Solution
NDC Package 0008-0423-03

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

North American Coral Snake Antivenin (equine) (coral snake (micrurus fulvius) immune globulin antivenin (equine)) injection is north American Coral Snake Antivenin (Equine) is indicated only for the treatment of envenomation caused by bites of North American coral snakes - Micrurus (including the eastern and Texas varieties). This formulation utilizes a injection, powder, for solution delivery system. Marketed by Wyeth Pharmaceuticals Llc, A Subsidiary Of Pfizer Inc., this product is identified by NDC 0008-0423 and is authorized under FDA application BLA101099.

Identification & Billing

NDC Package Code
0008-0423-03
Package Description
1 VIAL in 1 CARTON / 10 mL in 1 VIAL (0008-0423-01)
Product Code
0008-0423
11-Digit Billing Format
00008042303
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
1 EA
RxNorm Crosswalk
  • RxCUI: 1858981 - North American coral snake antivenin in 10 ML Injection
  • RxCUI: 1858981 - North American coral snake antivenin 250 UNT Injection
  • RxCUI: 1858981 - North American coral snake antivenin 250 [arb'U] per 10 ML Injection

Clinical Specifications

Proprietary Name
North American Coral Snake Antivenin (equine)
Non-Proprietary Name
Coral Snake (micrurus Fulvius) Immune Globulin Antivenin (equine)
Substance Name
Coral Snake (micrurus Fulvius) Immune Globulin Antivenin (equine)
Dosage Form
Injection, Powder, For Solution - A sterile preparation intended for reconstitution to form a solution for parenteral use.
Administration Route
Intravenous - Administration within or into a vein or veins.
Active Ingredient(s)
CORAL SNAKE (MICRURUS FULVIUS) IMMUNE GLOBULIN ANTIVENIN (EQUINE) 250 [arb'U]/10mL
Usage Information
North American Coral Snake Antivenin (Equine) is indicated only for the treatment of envenomation caused by bites of North American coral snakes - Micrurus (including the eastern and Texas varieties).

Regulatory & Marketing

Labeler Name
Wyeth Pharmaceuticals Llc, A Subsidiary Of Pfizer Inc.
Product Type
Human Prescription Drug
FDA Application #
BLA101099
Marketing Category
BLA - A product marketed under an approved Biologic License Application.
Start Marketing Date
10-12-2016
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 0008-0423-03 identifies a specific commercial package of 1 vial in 1 carton / 10 ml in 1 vial (0008-0423-01) of North American Coral Snake Antivenin (equine), a human prescription drug labeled by Wyeth Pharmaceuticals Llc, A Subsidiary Of Pfizer Inc.. This product is billed for "EA" each discreet unit and contains an estimated amount of 1 billable units per package. This injection, powder, for solution is formulated for intravenous use and contains coral snake (micrurus fulvius) immune globulin antivenin (equine) as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Wyeth Pharmaceuticals Llc, A Subsidiary Of Pfizer Inc. on October 12, 2016. The current certification is valid through December 31, 2026.

How is this Wyeth Pharmaceuticals Llc, A Subsidiary Of Pfizer Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 00008042303. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 1 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (4-4-2)
0008-0423-03
11-Digit CMS (5-4-2)
00008-0423-03

Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.